Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
NCT07199465 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (10)
California
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0006) — Los Angeles
- Lucile Packard Children's Hospital ( Site 0001) — Palo Alto
- University of California Davis Health ( Site 0023) — Sacramento
- UCSF Medical Center at Mission Bay ( Site 0017) — San Francisco
Colorado
- Children's Hospital Colorado ( Site 0013) — Aurora
Michigan
- University of Michigan ( Site 0014) — Ann Arbor
Minnesota
- Mayo Clinic - Rochester ( Site 0015) — Rochester
New York
- Morgan Stanley Children's Hospital ( Site 0018) — New York
North Carolina
- Duke University Medical Center ( Site 0008) — Durham
Ohio
- Cincinnati Children's Hospital Medical Center ( Site 0002) — Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-24 |
| Est. Completion | 2028-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07199465
The ClinicalTrials.gov registry entry for NCT07199465 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cytomegalovirus Prophylaxis appearing as the primary indexed condition, and to 1 intervention — of which Letermovir is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07199465 reports 10 study locations spanning 7 distinct geographic areas — top geographies include California, Colorado, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07199465 about?
NCT07199465 is a clinical study titled "A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)". Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of let...
What is the current status of trial NCT07199465?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-04-24. Estimated completion is 2028-05-19.
What conditions does trial NCT07199465 study?
This clinical trial studies the following conditions: Cytomegalovirus Prophylaxis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07199465?
The interventions under investigation include: Letermovir (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07199465?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07199465 being conducted?
This trial has 10 study locations across California, Colorado, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.